NewSpring Capital and Kineticos Life Sciences lead a $22 million investment in Kincell Bio, a cell therapy CDMO, and appoint industry veteran Pete Buzy to the board of directors
Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring Healthcare, which invests in innovative companies in the lower-middle market that improve the delivery of healthcare or bend the cost curve through technology and human capital efficiencies.